Minimal Residual Disease Market Set to Grow at 15.18% CAGR to Reach $3.73 Billion by 2030 with Growing Adoption of NGS and CAR-T Cell Therapy

InsightAce Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Minimal Residual Disease Market (By Indication ( Leukemia, Acute Lymphoblastic Leukemia (All), Chronic Lymphoblastic Leukemia (CLL), Acute Myeloid Leukemia (AML, Chronic Myeloid Leukemia (CML), Others, Lymphoma, Non-Hodgkin's Lymphoma (NHL), Marginal Zone Lymphoma, Follicular Lymphoma, Peripheral T-Cell Lymphoma, Mantle Cell Lymphoma, Others, Multiple Myeloma (MM), Solid Tumor, And Others), Detection (Next-Generation Sequencing (NGS), Flow Cytometry, Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH) And Others), Treatment Method (Chemotherapy, Stem Cell Transplant, Cart Cell Therapy And Others) And Treatment Centres (Hospitals, Oncology Treatment Centers, Diagnostic Centers & Research Institutions, Speciality Clinics And Others))- Market Outlook And Industry Analysis 2030"

The global minimal residual disease market is estimated to reach over USD 3.73 billion by 2030, exhibiting a CAGR of 15.18% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1448

Minimal residual disease (MRD) refers to leukemic cells that persist in a patient during or after cancer treatment. Standard cancer treatments, such as chemotherapy and radiotherapy, do not always eliminate all malignant cells and, in some cases, may contribute to cancer recurrence. MRD testing is often employed to enhance diagnostic precision, particularly in cases requiring major histocompatibility testing for organ transplants. The well-funded oncology testing market is expected to drive advancements in MRD technologies and enhance the specificity of testing, thereby supporting the growth of the MRD industry.

The rising prevalence of hematological malignancies and cancer, coupled with increasing healthcare expenditures, is anticipated to fuel the growth of the MRD market over the forecast period. Growing investments from both government and private sector entities in MRD research, along with increased consumer awareness of personalized therapies, are further driving market expansion. However, the high costs associated with research and development activities present a challenge to market growth.

Moreover, the increasing focus on research and development, the growing demand for personalized medicines, and a rise in product development collaborations create significant opportunities for market expansion. Additionally, the increasing demand for DNA testing, driven by advancements in next-generation sequencing (NGS) technologies, faster diagnostic outcomes, and cost advantages over genotyping-based DNA microarrays, is further contributing to market growth.

List of Prominent Players in the Minimal Residual Disease Market:
• Adaptive Biotechnologies
• ARUP Laboratories
• Bio-Rad Laboratories Inc.
• Cergentis B.V.
• F. Hoffmann-La Roche Ltd.
• ICON Plc
• Invivoscribe Inc.
• Laboratory Corporation of America Holdings
• Mission Bio
• Natera Inc.
• NeoGenomics Laboratories
• OPKO Health Inc.
• Sysmex Corporation

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics
Drivers
The expansion of the minimal residual disease (MRD) market is primarily driven by the increasing incidence of cancer and rising investment in research and development (R&D). The growing adoption of next-generation sequencing (NGS) technology is also contributing significantly to market growth. Furthermore, technological advancements in diagnostics and therapeutics, supported by increased R&D expenditure, are enhancing market expansion. Favorable initiatives from both government and private-sector entities aimed at advancing and adopting NGS technologies, along with improvements in cloud computing and the establishment of a robust healthcare research infrastructure, are further stimulating market growth. Additionally, a more favorable regulatory and reimbursement environment for NGS-based diagnostic tests and the expansion of genome mapping activities are expected to drive market growth throughout the forecast period.

Challenges
High R&D costs present a significant challenge to market growth. The healthcare, industrial, technological, and pharmaceutical sectors often face substantial R&D expenses. Despite notable progress in expanding NGS applications from research to clinical settings, challenges remain in managing quality control, data processing, storage, and interpretation. These obstacles hinder the transition of NGS from research to practical clinical use, thereby restraining market growth.

Regional Trends
North America is projected to hold a leading share of the MRD market during the forecast period, driven by increasing healthcare expenditures in the United States. The expansion of drug discovery platforms requiring NGS technology and the heightened focus on developing treatments and diagnostics for detecting MRD are supporting market growth in the region. Meanwhile, the Asia-Pacific region is also expected to secure a notable market share. The rising number of healthcare facilities in emerging markets across Asia-Pacific is creating substantial growth opportunities for the MRD industry.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1448

Recent Developments:
• In October 2021-Inivata Limited Company, a subsidiary of NeoGenomics, Inc., engaged in a clinical partnership with the Princess Margaret Cancer Center in Toronto, Canada, to employ Inivata's InVisionFirst-Lung & RaDaR liquid biopsy assays in two separate studies.
• In May 2021-Invivoscribe company, for example, announced licensing of critical software and two new minimal residual disease clinical services. LymphoTrack Enterprise Software from the company helped high-volume customers manage escalating testing demands.
.
Segmentation of Minimal Residual Disease Market-
By Indication
• Leukemia
o Acute Lymphoblastic Leukemia (All)
o Chronic Lymphoblastic Leukemia (CLL)
o Acute Myeloid Leukemia (AML)
o Chronic Myeloid Leukemia (CML)
o Others
• Lymphorma
o Non-Hodgkin's Lymphorma (NHL)
o Marginal Zone Lymphorma
o Follicular Lymphorma
o Peripheral T-cell Lymphorma
o Mantle Cell Lymphorma
o Others
• Multiple Myeloma (MM)
• Soild Tumor
• Others
By Dectection
• Next-Generation Seqencing (NGS)
• Flow Cytomerty
• Polymerase Chain Reaction (PCR)
• Fluorescence In-Situ Hybridzation (FISH)
• Others
By Treatment Methods
• Chermotherapy
• Stem cell Transplant
• CAR-T Cell Therapy
• Others
ByTreatment Centers
• Hospitals
• Oncology Treatment Centers
• Diagnostic Centers & Research Institutions
• Specialty Clinics
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.